Yuxian Bai

Also affiliated with Third Affiliated Hospital of Harbin Medical University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.”.

Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.

Journal of Clinical Oncology(2019)10.1200/jco.2019.37.15_suppl.4117

N/A

2.8DataRank · unranked

78 citations

Yin-Hsun Feng, Yen-Yang Chen, Wu-Chou Su, Do-Youn Oh, Lin Shen +12 more

Pembrolizumab in HER2-Positive Gastric Cancer

New England Journal of Medicine(2024)10.1056/nejmc2408121

N/A

1.4DataRank · unranked

65 citations

Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges +21 more